InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
ClayTrader Free
09/15/20 5:34 PM
profile icon
hedge_fun Free
09/15/20 10:52 AM
profile icon
wesley_ PremiumMember
09/15/20 10:40 AM
profile icon
beebread Free
07/21/20 4:41 PM
profile icon
beebread Free
07/09/20 7:24 PM
profile icon
beebread Free
06/15/20 4:11 PM
profile icon
beebread Free
06/12/20 8:46 PM
profile icon
anthjr87 Free
06/01/20 2:33 PM
profile icon
ClayTrader Free
05/14/20 6:11 PM
profile icon
swingingRichard Free
05/13/20 11:22 PM
profile icon
ClayTrader Free
05/13/20 4:26 PM
profile icon
wesley_ PremiumMember
04/22/20 9:32 AM
profile icon
wesley_ PremiumMember
04/21/20 2:30 PM
profile icon
ClayTrader Free
01/30/20 5:56 PM
profile icon
ClayTrader Free
12/10/19 5:49 PM
profile icon
europtiger Free
12/10/19 2:31 PM
profile icon
TFMG Free
05/24/19 7:30 PM
profile icon
willlbone Free
04/22/19 3:05 PM
profile icon
Mark PremiumMember
01/31/19 8:28 PM
profile icon
ClayTrader Free
09/07/18 5:14 PM
profile icon
TheFinalCD PremiumMember
09/07/18 9:20 AM
profile icon
FairviewInvestor Free
06/25/18 1:29 PM
profile icon
FairviewInvestor Free
06/18/18 1:41 PM
profile icon
FairviewInvestor Free
05/15/18 3:22 PM
profile icon
FairviewInvestor Free
05/14/18 2:43 PM
profile icon
ash111 Free
04/16/18 3:25 AM
profile icon
Mark PremiumMember
04/15/18 7:32 PM
profile icon
ash111 Free
04/03/18 10:57 AM
profile icon
FairviewInvestor Free
03/16/18 4:31 PM
profile icon
ash111 Free
03/16/18 3:49 PM
profile icon
FairviewInvestor Free
03/15/18 1:42 PM
profile icon
toomorrow Free
03/15/18 12:43 PM
profile icon
Giddycarol30 Terminated
03/14/18 11:39 PM
profile icon
FairviewInvestor Free
03/14/18 1:38 PM
profile icon
Giddycarol30 Terminated
03/14/18 1:07 PM
profile icon
FairviewInvestor Free
03/14/18 12:37 PM
profile icon
Giddycarol30 Terminated
03/14/18 12:32 AM
profile icon
FairviewInvestor Free
01/02/18 4:59 PM
profile icon
FairviewInvestor Free
06/29/17 3:11 AM
profile icon
FairviewInvestor Free
06/20/17 9:38 PM
profile icon
FairviewInvestor Free
05/25/17 3:15 PM
profile icon
FairviewInvestor Free
05/25/17 3:14 PM
profile icon
FairviewInvestor Free
05/25/17 3:14 PM
profile icon
FairviewInvestor Free
05/25/17 3:14 PM

Novus Therapeutics Inc fka NVUS RSS Feed

Followers
19
Posters
114
Posts (Today)
0
Posts (Total)
625
Created
09/17/14
Type
Free
Moderators


Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a delivery vehicle for drugs treating ears, as well as the nasal and sinus cavities. OP-01 is currently being developed as an improved treatment option for acute otitis externa. OP-02 is a daily nasal spray that is designed to improve and maintain a healthy middle ear. OP-02 is being developed as a potential treatment option for patients with otitis media and Eustachian tube dysfunction. OP-02 is a combination drug product, which comprises two components: surfactant dipalmitoylphosphatidylcholine and a spreading agent cholesteryl palmitate. The product is sprayed through the nostrils toward the opening of the Eustachian tube at the back of the nasal cavity.


36.9% of Tokai Pharmaceuticals shares are owned by institutional investors. 39.9% of shares are owned by insiders.


Novus Therapeutics is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat (ENT) products. The company has two technologies, each of which has the potential to be developed for multiple ENT indications. The company's lead product is a nasally-administered, combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD), conditions that affect more than 700 million people around the world every year. Otitis media is one of the most common diseases seen by pediatricians and the most frequent reason children consume antibiotics or undergo surgery. The company also has a foam-based drug delivery technology platform (OP-01) that can be used to deliver drugs into the ear, nose, and sinus cavities. The company is currently developing a foam-based combination drug-product delivered to the external ear canal that is an improved treatment option for acute otitis externa ("swimmers ear").

HeadquartersIrvine, California, United States

Investor Contacts

Novus Therapeutics, Inc.
Investor Relations
Tel: (949) 238-8090
investors@novustherapeutics.com
Board Info
Posts Today
0
Posts (Total)
625
Posters
114
Moderators
New Post